(Q41950850)

14 October 2017

In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe (English)

1 reference

14 October 2017

gram-positive bacteria

0 references

author name string

W T M Jansen

1

1 reference

14 October 2017

A Verel

2

1 reference

14 October 2017

J Verhoef

3

1 reference

14 October 2017

D Milatovic

4

1 reference

14 October 2017

language of work or name

English

0 references

publication date

2 July 2007

1 reference

Antimicrobial Agents and Chemotherapy

14 October 2017

1 reference

14 October 2017

51

1 reference

14 October 2017

9

1 reference

14 October 2017

3420-3424

1 reference

Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study

14 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043219

Recent developments in glycopeptide antibacterials

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043219

Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043219

Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043219

Glycopeptides in clinical development: pharmacological profile and clinical perspectives.

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043219

In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic gram-positive species and Corynebacterium spp

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043219

In vitro activity of TD-6424 against Staphylococcus aureus

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043219

Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria

5 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043219

Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2043219

Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus

18 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17606689

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1128/AAC.00100-07

1 reference

14 October 2017

1 reference

14 October 2017

PubMed publication ID

17606689

1 reference